Adenovirus vectors have several features that make them attractive for potential use in gene therapy, including a broad tissue tropism and an ability t o infect quiescent or postmitotic cells. In light of this, we examined whether recombinant adenovirus vectors could transfer genes into neoplastic cells of patients with chronic lymphocytic leukemia (CLL), a leukemia of "resting" B cells. Using high-titer recombinant adenovirus vectors, we found we could transfer genes encoding P-galactosidase or murine CD80 (87-1) into the CLL B cells of all patients tested (n = IO). The efficiency of gene transduction into CLL B cells was approximately 100 t o 1,000-fold lower than into HeLa cells at any given multiplicity of infection (MOI). At a MO1 of 500, 10% t o 70% of the CLL B cells from different patients were made t o express the transgene, as assessed by multiparameter flow cytometric analysis. Sustained levels of expression with little loss in the percentage of infected cells were maintained for up t o 9 days, at which point the analysis was stopped. We found that CLL B cells have markedly lower expression levels of integrins that facilitate internalization of adenovirus -CELL CHRONIC lymphocytic leukemia (CLL) is the most common adult leukemia in Western societies. Despite recent advances, CLL still is not considered curable,' thus mandating improved treatment strategies for this disease. In some respects, the disease should be amenable to gene therapy. As the leukemia cells are readily accessible, it is feasible to obtain large, relatively pure, populations of neoplastic cells for genetic modification with virus or nonvirus gene transfer vectors ex vivo. Furthermore, because patients with CLL often have impaired immunity,' it may be possible to use virus vectors in CLL patients that otherwise might induce immune responses that can interfere with the virus-vector-delivery and/or Finally, although CLL B cells generally are ineffective stimulator cells in mixed lymphocyte reactions, they express high levels of class I and class I1 HLA antigens and can be activated in vitro to become efficient antigen presenting Conceivably, transfection of CLL cells with vectors that encode stimulatory immune accessory molecules and/or cytokines could induce a therapeutic host antileukemia immune response.
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However, CLL B cells generally are resistant to most currently available gene transfer techniques (eg, electroporation, lipofection, or amphotropic retrovirus infection). Most leukemia cells are noncycling, making it impossible to employ many methods of gene transfer. Furthermore, even if the leukemia cells are induced to divide in vitro, gene transfer is
The publication costs of this article were defrayed in part by page charge payment. This article must therejore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate rhis fact. not efficient. At best, only a small proportion of CLL B cells can be transfected via electroporation, and then only after preactivation.' The low efficiency of gene transfer has prompted us to explore new avenues for introducing genes into CLL cells.
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Adenovirus vectors are potentially suitable for transferring genes into CLL B cells. Adenovirus is a 36-kb doublestranded DNA virus that can infect many different types of cells efficiently and with low pathogenicity.8 In particular, adenovirus vectors can introduce foreign genes into nonreplicating cells, theoretically making them good candidate vectors for gene transfer into postmitotic CLL B cells. Another advantage is that adenovirus vectors are relatively stable and can be produced and concentrated to high titers, making it feasible to infect cells at a relatively high multiplicity of infection (MOI).' Finally, the adenovirus genome generally does not integrate into the chromosomal DNA of the infected cell, mitigating hypothetical concern over insertional mutagenesis.
Most current adenovirus vectors carry deletions in the immediate-early genes EIA, ElB, and/or E3, making these vectors defective for replication in cells that do not express such virus genes in trans. Io Such replication-defective adenovirus vectors can be propagated in the human kidney cell line, 293, a cell line that constitutively expresses the adenovirus El gene.'' For these studies, we examined the ability of such vectors to infect CLL B cells in vitro. Construction of adenovirus vectors and adenovirus infection. An adenovirus vector expressing lacZ, designated adeno-lacZ, was constructed by cotransfecting pJM17I5 and pHCMVsplLacZ (a gift from A.J. Bett, Ontario, Canada) into 293 cells obtained from ATCC. The expression level of the lacZ transgene was determined by the fluorescence P-galactosidase assay. For construction of the murine CD80 adenovirus vector, designated adeno-mB7, the murine CD80 cDNA'~ (a gift from James P. Allison (UC Berkeley, Berkeley, CA) was subcloned into pBluescript (Stratagene). The murine CD80 cDNA was cloned into the plasmid pRc/RSV (Invitrogen, San Diego, CA) at the HindIII-Xbal site. A BgIII-Xhol fragment with the "RSV promoter enhancer and the bovine growth hormone poly-A signal sequence was subcloned into the BamHI-Xhol site of plasmid MCS(SK)pXCX2. The plasmid MCS(SK)pXCX2 is a modification of the plasmid pXCX2,I5 in which the pBluescript polylinker sequence had been cloned into the El region (J.R. Tozer, UCSD, unpublished data, September 1993). The resulting plasmid was then cotransfected along with pJM17I5 into 293 cells using the calcium phosphate method." Isolated plaques of adenovirus vectors were picked and expanded by infecting 293 cells. High-titer adenovirus preparations were obtained as described,15 except for the following modifications. The cesium chloride gradient used for concentrating virus particles was a step gradient, with the densities of 1.45 g/cm3 and 1.20 g/cm3. Samples were centrifuged for 2 hours in a SW41 rotor (Beckman, Brea, CA) at 25,000 rpm at 4°C. The virus band was desalted using a Sephadex G-25 DNA grade column (Pharmacia, Piscataway, NJ), and the isolated virus was stored at -70°C in phosphate-buffered saline with 10% glycerol. The titer of the virus was determined by infecting permissive 293 cells at various dilutions and counting the number of plaques. Titers typically ranged from 10" to lo'' plaque forming units/&.
MATERIALS AND METHODS
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For adenovirus infection, IO6 freshly thawed and washed CLL cells or HeLa cells were suspended in 0.5 to 1 mL of culture medium for culture at 37°C in a 5% C02-in-air incubator. Adenovirus was added to the cells at varying MOI, and the infected cells were cultured for 48 hours, unless otherwise stated, before being analyzed for transgene expression.
CD32-L cell assay. CLL B cells were stimulated on a monolayer of CD32 L cells in 6-well tissue culture plates (Coming Glass Works, Coming, NY) for various times in the presence of 250 ng/mL a-CD40 or MOFC 21 control MoAb, as de~cribed.~ Multiparameterflow cytometric analysis. Beta-galactosidase activity was measured by flow cytometry, as described." This method makes use of a fluorogenic substrate, fluorescein di-P-D-galactopyranoside (FDG), that is hydrolyzed by P-galactosidase and then retained inside the cell, allowing the cells to fluoresce green light when excited at 488 nm. For this, the cells were washed in staining media (SM) consisting of RPMI-1640, 3% fetal calf serum, and 0.05% sodium azide. The cells were suspended in 100 pL SM and incubated for 10 minutes at 37°C before adding 100 pL of 2 mmoVL FDG in triple-distilled H20. After 1 minute at 37°C the reaction was stopped by adding 2 mL of ice cold SM containing propidium iodide at 10 ng/mL. To examine for expression of surface antigens, the cells were washed and then suspended in SM containing saturating amounts of FITC-or PE-conjugated MoAbs against various cell surface antigens or isotype specific control MoAbs, as described." After 30 minutes at 4"C, cells were washed in SM containing propidium iodide and then analyzed on a FACScan (Becton Dickinson, San Jose, CA). Dead cells and debris were excluded from analysis by characteristic forward and side light scatter profiles and propidium iodide staining. Surface antigen expression was measured as the mean fluorescence intensity ratio (MFIR). MFIR equals the mean fluorescence intensity (MFI) of cells stained with a specific FITC-conjugated MoAb, divided by the MFI of cells stained with a control IgG-FITC. This method controls for the nonspecific increases in auto-fluorescence seen in larger, more activated cells.
RESULTS
Adenovirus-mediated gene transfer into CLL B cells.
Leukemia B cells from CLL patients (n = 10) were incubated with adeno-lacZ or adeno-mCD80 at various MOL For comparison, the same virus vectors were used to infect HeLa cells. Forty-eight hours after infection, the cells were washed and examined for expression of the transgene product, pgalactosidase or murine CD80, respectively. The leukemia cells from each sample were found to express the transgene when infected with either adenovirus vector at an MO1 of 2500, as assessed by flow cytometry (Fig 1, and data not shown). The proportion of cells expressing /?-galactosidase after infection with adeno-1acZ in each sample increased with increasing MOI. The MO1 found to effect transgene expression in 50% of the infected cells (IDSo) ranged from 200 to 2,000, depending on the leukemia cell sample (Fig  1) . Similar levels of infection and transgene expression also were seen using the murine CD80 adenovirus vector, adenomCD80 (Fig 2) . In contrast, HeLa cells were much more susceptible to adenovirus infection, manifesting an IDso of approximately 2 with either virus vector (Figs 1 and 2 , and data not shown). Nevertheless, the expression levels of the murine CD80 on adeno-mCD80-infected CLL cells were similar to those of adeno-mCD80-infected HeLa cells (Fig  2) . Treatment of the adenovirus vectors for 20 minutes at 56°C before infection destroyed their ability to effect transgene expression at any MO1 (data not shown).
We evaluated the time required for optimal adenovirus infection of CLL cells or HeLa cells in vitro. At time t , , , the adenovirus vector was added to the cells. The cells were cocultured with the adenovirus for 30 minutes, 3 hours, or 24 hours, washed, and then suspended in medium for repeat culture at 37°C without additional adenovirus vector. The cells were examined for transgene expression at b8, or 48 hours after adding the adenovirus vector. Parallel control cultures of cells incubated with adenovirus vector for 48 hours were used to determine the maximum proportion of transgene-expressing cells achieved for a given MOL We found that the proportion of cells expressing the transgene at increased with the time of coculture. The proportions of CLL cells expressing the mCD80 transgene at 4 8 were 9%, 19%, or 100% of the maximum proportion when they were incubated with the adeno-mCD80 vector for only 30 minutes, 3 hours, or 24 hours, respectively. In contrast, the proportions of HeLa cells expressing the mCD80 transgene after coculture with the adeno-mCD8O vector exceeded 95% of that seen for cells continuously cocultured with the virus at all time points. These data suggest that the adenovirus vector binds to these cells more effectively than to CLL cells, allowing for more efficient infection of HeLa cells at any given MOL Repeated experiments demonstrated that the leukemia cells from different patients differed in their relative susceptibility to infection with the adenovirus vectors. Although the mean IDs0 for all leukemia cell samples was approximately 1,000 (t standard deviation [SDI = 677), we find the leukemia cells from two patients (patients no. 1 and no. 4, Fig 1) infected with adeno-lacZ at an MO1 of 1,000 resulted in 72% and 60% of the cells expressing the transgene, respectively, while the leukemia cells from remaining patients had values that were significantly lower (mean percentage = 21% ? 7.1, P < .005, Student's t test). This variation in susceptibility to infection exceeded the variation noted in repeated experiments on leukemia cells from any one donor. For example, 40% or 36% of the leukemia cells of patient no. 4 (Fig 1) were found to express ,&galactosidase 48 hours after coculture with either of two adeno-lacZ vector preparations at an MO1 of 500. Using these vectors at a similar MO1 of 100, only 13%, 9%, or 12% of the leukemia cells from patient no. 2 were found to express the transgene in separate experiments.
Expression of integrins involved in internalization of adenovirus. Prior studies indicated that the vitronectin-binding integrins a& and a& promote adenovirus infection by facilitating virus internalization without affecting attachment.*' Although adenovirus binds to cultured cell lines lackFor personal use only. on October 3, 2017. by guest www.bloodjournal.org From A. MOI=2 C. 
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ing a,P3 and a&, it does not intemalize efficiently, thus diminishing its ability to infect such cells. Because our adenovirus vectors were able to infect CLL B cells, we anticipated that leukemia cells would express these integrins. However, we found that each leukemia cell sample lacks expression of detectable amounts of a,p5 (mean MFIR = l), and expresses low, but detectable, levels of a.,& (mean MFIR = 1.5, n = 3). Furthermore, we did not detect any significant differences in the expression levels of these integrins between leukemia populations that had a relatively high susceptibility to infection (patients no. 1 and no. 4, Fig  1) and those with lower levels of susceptibility (data not shown). In contrast, HeLa cells were found to express relatively high levels of a& (MFIR = 16.4) and low levels of Because B-cell activation via CD40-signaling induces expression of a variety of cell surface molecules that are important in cognate cell-cell interactions, we examined whether CD40 cross-linking could induce expression of avo3 or a,p5. We find that the leukemia cells from each patient a,P3 (MFIR z= 1.3). tested (n = 9) expressed higher levels of a& and a,p3 after 24 hours culture with anti-CD40 MoAb and CD32-expressing L cells (Fig 3, and data not shown) . The mean MFIR of activated leukemia cells (n = 9) stained with fluorochrome-conjugated anti-a,p5 was 4. 
gene transfer, parallel cultures of HeLa cells were infected with the same virus preparation at various MOI. We found that, at any given MOI, a higher proportion of the CD40-activated CLL B cells expressed the lacZ transgene compared with the control nonstimulated CLL B cells (Fig 4) . For any given leukemia cell population, the ID5,, decreased approximately fivefold. Nevertheless, the transduction efficiency of HeLa still exceeded that of activated CLL B cells. We assessed the levels of transgene expression in adenovirusinfected cells in vitro as a function of time after infection. We observed sustained expression of &galactosidase for both resting and CD40-activated CLL cells infected with adeno-lacZ virus vector (Fig 5) . The proportions of cells expressing the transgene declined slowly over a period of 7 to 10 days in either leukemia population. However, even at 9 days postinfection, the proportions of leukemia cells found to express the transgene were 260% of that noted at 24 hours (Fig 5) . We demonstrated that adenovirus vectors can transduce genes into leukemia B cells. This contrasts with the conclusions made by investigators of another recent study, who suggested that CLL B cells from most patients were impervious to adenovirus infection.** Although these investigators noted that adenovirus could not infect the neoplastic cells of various hematologic malignancies, including CLL, they limited the MO1 for each sample to ~4 0 0 .
In contrast, using a MO1 of 2500, we find that adenovirus type 5 E l and 
E3-deleted vectors, expressing reporter genes encoding p-
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not result from passive uptake of protein from the adenovirus preparations. Incubation at 56°C for 20 minutes destroys the ability of adenovirus to infect cells, but does not inactivate @-galactosidase pr~tein.*~-*~ Nevertheless, leukemia cells infected with adeno-lacZ that had been so treated failed to have any detectable P-galactosidase activity at any given MOI, demonstrating that adenovirus infection is required for expression of the lacZ transgene in leukemia cells. We used flow cytometric methods to evaluate cells for expression of P-galactosidase. Although more sensitive than traditional immunohistochemical techniques,26 the method can be highly specific for measuring P-galactosidase activity." Furthermore, the flow cytometric assay allows for more reliable measurement of the proportions of cells that express P-galactosidase than immunohistochemical methods. Moreover, the proportions of cells expressing P-galactosidase at any given MO1 using the adeno-lacZ vector were similar to those of cells found to express murine CD80 following infection with adeno-mCD80 at a comparable MOI. The latter helps verify that the flow cytometric method is a reliable means to evaluate for cells expressing the lacZ transgene.
We identified two levels of leukemia cell susceptibility to adenovirus infection. The infection efficiency varied between leukemia cell samples from different patients, but remained relatively constant for the cells of any given patient. More susceptible leukemia cells were found to have an ID50 of approximately 200 MOI, whereas leukemia cells in the less susceptible group manifested an ID5,, of approximately 2,000 MO1 (Fig 1, and data not shown) . However, the differences in infection susceptibility between leukemia populations were small compared with that noted between HeLa cells and CLL cells in general. Indeed, we have found that the infection efficiency of adenovirus vectors for HeLa cells is 100 to 1,000 times greater than it is for any of the examined leukemia cell samples.
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Prior studies have established that there are at least two steps required for adenovirus to gain entry into a cell.27 The first step requires the binding of the adenovirus to a putative cell surface receptor(s). Currently, this receptor(s) has not been identified. The second step requires that the adenovirus enter the cell. Wickham et alZo reported that the integrins a& and m,p5, while not being required for virus attachment to the cell, are required for efficient internalization of the attached virus. Conceivably, the differences in infection susceptibility noted between HeLa cells and CLL B cells, and also between leukemia samples from different donors, may be related to differences in expression of receptors for attachment, internalization, or some combination of the two.
However, it is unlikely that differences in the levels of integrin expression could account for the differences in susceptibilities of different CLL samples to adenovirus infection. Indeed, we did not detect any significant differences between leukemia cells in their relative expression of integrins that facilitate adenovirus internalization. Instead, we found that the nontreated leukemia B cells from each patient express low, but detectable, amounts of a&, and no detectable a& (Fig 3 and data not shown) . In contrast, the highly permissive HeLa cells express high levels of a,ps and low, but detectable, amounts of a&.
The differences in expression of integrins by leukemia cells and HeLa cells apparently cannot entirely account for the differences in the infection susceptibilities of HeLa versus CLL B cells. Indeed, we found that CD40 cross-linking induces surface expression of aVp5 and avp3 on the leukemia cells of each patient studied to levels comparable to that of HeLa cells (Fig 3) . The relative increase in expression of a,pS exceeded that noted for a&, possibly reflecting the fact that nonstimulated CLL B cells do not express detectable amounts of the former integrin. The increased expression levels of these integrins were associated with a fivefold increase in susceptibility to adenovirus infection of activated leukemia cells. However, the prolonged coculture of the CLL cells with the adenovirus vectors that was required for infection precluded inhibition studies, testing whether antibodies or RGD peptides could inhibit the enhanced susceptibility of activated CLL cells to adenovirus infection." In any case, although the increase in expression of these integrins is associated with an increased susceptibility to adenovirus infection, the enhanced susceptibilities noted for any activated CLL cell sample still were substantially lower than that noted for HeLa cells (Fig 4) .
Conceivably, differences between CLL B cells and HeLa cells in their relative expression of the putative adenovirus receptor(s) may account for the large difference in their susceptibility to adenovirus infection. Consistent with this notion we find that continuous coculture for 24 hours of CLL cells with the adenovirus vector was required for maximum infection, whereas a 30-minute co-culture of HeLa cells with adenovirus seemed sufficient. Furthermore, we find that the slopes defining the increase in the proportion of cells made to express the transgene relative to increases in MO1 are steeper for HeLa cells (slope = 6.6) than for CLL B cells (slopes = 0.006 to 0.06), even after the threshold MO1 for detecting transduced cells is reached for each cell type. For HeLa cells, we discern increasing proportions of cells expressing the transgene with increasing MO1 above a threshold MO1 of approximately 0.2. In contrast, the mean MO1 thresholds for discerning increases in the proportion of transgene expressing cells are approximately 20 or 100 for activated or resting CLL B cells, respectively. These M01 are only 10-to 50-fold greater than the threshold MO1 required for HeLa cells. In contrast, the ID,, MO1 required to induce expression of the transgene in 50% of the cells are.
respectively, 50-to 250-fold greater for either activated or resting CLL cells versus that for HeLa cells. As such, methods to concentrate the virus and leukemia cells further during the initial infection may not overcome the differences in adenovirus infection efficiencies noted between HeLa and CLL B cells. Preliminary studies have shown this to be the case (data not shown).
Nevertheless, adenovirus vectors offer a novel, effective, and potentially useful means to introduce genes into CLL B cells. We find that high proportions of resting CLL B cells can be made to express a transgene with adenovirus vectors at high MOL Improved adenovirus culture techniques now allow for production of adenovirus vectors with titers of 2 10'" PFU/mL or more. Thus, it is possible to consider use of adenovirus vectors to transduce large numbers of resting CLL cells. Furthermore, because these cells are noncycling, transgene expression is relatively stable. Of course, the duration of expression of transgenes can depend on factors, such as gene product function andor stability, that may vary greatly from one protein to another.
Adenovirus vectors may afford a means for new therapeutic strategies for CLL. For example, tumor cells transduced to express immune accessory molecules, such as CD80, and/ or cytokines, such as interleukin-2 or granulocyte-macrophage-colony-stimulating-factor (GM-CSF), have been found to have enhanced immunogenicity in experimental animal models (reviewed in Dranoff and M~lligan'~). Such modified tumor cells can elicit host immune responses effective against the nontransduced parent tumor cell population. Conceivably, adenovirus infection of CLL cells to bring about expression of transgenes that encode such immunostimulatory molecules also may allow these cells to act as cellular vaccines capable of eliciting host antileukemia cell immunity. However, it remains to be seen whether genetically-modified CLL cells can act as effective cellular vaccines. Nevertheless, the finding that adenovirus can infect CLL cells suggests new strategies to treat this disease.
